Pharmacogenetic variants and risk of remdesivir-associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID-19COVID-19로 입원한 백만 재향 군인 프로그램 참가자의 약물 유전적 변이 및 렘데시비르 관련 간 효소 상승 위험Article Published on 2022-08-012022-09-11 Journal: Clinical and translational science [Category] COVID19(2023년), SARS, 변종, [키워드] adjusted administration age Alanine alanine aminotransferase ALT assigned association baseline black Comorbidities components conducted coronavirus disease Coronavirus disease 2019 COVID-19 CYP2C19 drug Drug administration Elevation enzyme food Hospitalized Linear regression liver enzyme liver enzymes log-transformed Million Veteran Program multifactorial multivariable model participant Participants Patient pharmacogenetic phenotype receiving Remdesivir retrospective risk Sex stratified Treatment treatment initiation variant was performed white with COVID-19 [DOI] 10.1111/cts.13313 PMC 바로가기 [Article Type] Article
Effects of pharmacological and genetic regulation of COMT activity in alcohol use disorder: a randomized, placebo-controlled trial of tolcapone Research Published on 2022-05-062022-10-05 Journal: Neuropsychopharmacology [Category] 임상, [키워드] Activation alcohol baseline characterized COMT cortical Effect enzyme Genetic Genotype genotyped groups inactivation individual inhibition inhibitor lab less medication not affect outcome participant pharmacogenetic pharmacological Placebo placebo-controlled placebo-controlled trial Randomized reduce reduced Regulation responsible Signaling These data Tolcapone Trial [DOI] 10.1038/s41386-022-01335-z [Article Type] Research
Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 TherapiesPharmacology Published on 2022-02-182022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] ABCB1 ABCC2 accelerate Administered anti-SARS-CoV-2 APOA5 association CES1 clinical effectiveness clinical settings Compound Computational study conditions coronavirus disease COVID-19 COVID-19 patient COVID-19 therapy CYP2B6 CYP2C19 CYP2C9 described docking drug Drug-drug interactions drug-herb interactions drug–drug interaction drugs effective Evidence FCGR3A feasible HLA improvement in silico information Interaction Intervention Medicine molecular docking multifactorial non-steroidal anti-inflammatory drug pandemic pathogenesis and severity pharmacogenetic pharmacogenetics pharmacokinetic Precision precision medicine Repurposed drug Repurposed drugs SARS-COV-2 infection SLC28A2 SLCO1B1 SLCO1B3 target therapy these compound UGT1A1 unlikely VKORC1 [DOI] 10.3389/fphar.2022.835136 PMC 바로가기 [Article Type] Pharmacology
Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort StudyArticle Published on 2021-11-122022-10-30 Journal: Journal of Personalized Medicine [Category] COVID-19, [키워드] chronic conditions chronic obstructive clinically COPD COVID-19 COVID-19 patients determine diabetes disease drug drug interaction greater Health healthcare administration healthcare costs hierarchical conditions category (HCC) Hospitalization Hospitalized hyperlipidemia hypertension identify indicate Interaction interactions Length Length of stay likelihood LOS Medicare medication management member moderate outcome Patient patients hospitalized pharmacogenetic pharmacogenomics PIP precision medicine Probability pulmonary disease reduce risk risk adjustment factor (RAF) severely ill patients significantly with COVID-19 [DOI] 10.3390/jpm11111192 PMC 바로가기 [Article Type] Article
Complex analysis of the personalized pharmacotherapy in the management of COVID-19 patients and suggestions for applications of predictive, preventive, and personalized medicine attitudeResearch Published on 2021-07-162022-10-31 Journal: The EPMA Journal [Category] COVID-19, [키워드] all ethnic groups alpha-2b analysed Analysis antiviral agent approach Biomarker calculated ceftriaxone Characteristics Chloroquine clinical Clinical practice clinical trial Colchicine collected Comorbidities comprehensive analysis Coronavirus disease 2019 COVID-19 COVID-19 patient daclatasvir defined Dexamethasone drug Drug efficacy Drug score drug therapy Drug-to-drug interaction drugs ethnic group Ethnicity-based differences evaluate facilitate Frequency functional Future healthcare Gene score generate genetic difference genetic differences genetic test HCQ highest human immunoglobulin human immunoglobulin G Hydroxychloroquine immune regulator indicated Individual outcomes individuals interferon interferon alpha-2b Interferon beta-1a levofloxacin Lopinavir losartan management molecular mechanisms Optimal medication patients with comorbidity performed Personalized medicine personalized treatment pharmacogenetic pharmacogenetics pharmacogenomics Predictive Predictive preventive personalized medicine (PPPM/3 PM) Prednisone Remdesivir reported Result ribavirin Ritonavir significantly sofosbuvir suggested supplementary material the patient translation Treatment Trial Variation variations Zinc [DOI] 10.1007/s13167-021-00247-0 PMC 바로가기 [Article Type] Research
Pharmacogenomic landscape of COVID-19 therapies from Indian population genomes인도 인구 게놈에서 코로나19 치료제의 약리유전체학적 풍경Article Published on 2021-07-012022-09-11 Journal: Pharmacogenomics [Category] SARS, 변종, 유전자 메커니즘, 치료제, [키워드] ABCB1 ALB analyzed candidate clinical decision clinically COVID-19 COVID-19 therapeutics covid-19 therapies COVID-19 therapy COVID-19 treatment CYP3A4 Deleterious drug drug-drug interaction Drug–drug interactions drug–drug–gene interactions drugs Evidence Genome Indian population individual inhibitor Interaction material metabolic disorder Numerous overlapped Patient pharmacogenetic pharmacogenomics pharmacogenomics. populations predicted therapy Treatment validation study variant variants whole genome whole genomes with COVID-19 [DOI] 10.2217/pgs-2021-0028 PMC 바로가기 [Article Type] Article
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies향정신성 제제와 용도 변경 COVID-19 치료제 간의 임상적으로 중요한 약물 상호작용Review Published on 2021-04-012022-09-11 Journal: CNS drugs [Category] MERS, 신약개발, 유전자 메커니즘, 치료제, [키워드] acting agent clinically concomitant use COVID-19 COVID-19 therapy cytochrome P450 drug drug interaction Drug interactions drug-drug interaction expected infected with COVID-19 Interaction management Manifestations mechanism P450 Patient pharmacogenetic pharmacokinetic polymorphism Polymorphisms Psychiatric psychiatric disorder Psychiatric disorders Psychotropic psychotropic agent psychotropic agents Psychotropic medication psychotropic medications raise recommendation responsible resulting severity severity of illness Significant Stage subject synergistic Therapies therapy Toxicity [DOI] 10.1007/s40263-021-00811-2 PMC 바로가기 [Article Type] Review
Pharmacogenetics Approach for the Improvement of COVID-19 Treatment코로나19 치료 개선을 위한 약물유전학 접근법Review Published on 2021-03-052022-09-10 Journal: Viruses [Category] SARS, 변종, 유전자 메커니즘, 치료제, [키워드] (remdesivir ABCB1 ABCC2 addition Azithromycin Chloroquine complex coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 treatment CYP2C8 CYP2D6 CYP3A4 CYP3A5 Dexamethasone drug drug response drug–drug interaction Drug–drug interactions Efficacy evaluated explain Factor Hydroxychloroquine IMPROVE improvement Inflammation Ivermectin Lopinavir NR1I2 oseltamivir other variants outcome pharmacogenetic pharmacogenetics Remdesivir reported Ritonavir SLCO1B1 therapy Treatment Variability variant variants Variation [DOI] 10.3390/v13030413 PMC 바로가기 [Article Type] Review
Investigation of Genetic Variations of IL6 and IL6R as Potential Prognostic and Pharmacogenetics Biomarkers: Implications for COVID-19 and Neuroinflammatory DisordersCommunication Published on 2020-12-162022-10-29 Journal: International Review of Cell and Molecular Biology [Category] COVID-19, [키워드] Affect binding ability Biomarker Biomarkers Complication COVID-19 disease Diseases disorder distribution expression FIVE General population Genes genetic variants Genetic variation IL6 IL6R implicated IMPROVE Ingenuity Pathway Analysis investigated investigation IPA Italian mechanism Mortality multiorgan failure neurodegenerative neurodegenerative disorders Neuroinflammation Personalized medicine pharmacogenetic pharmacogenetics pleiotropic Potential predicted Prevent Prognosis prognostic progression protocol public health Quality of life rs2228145 SARS-CoV-2 Seven severity susceptibility treatment strategy variant was performed with COVID-19 [DOI] 10.3390/life10120351 PMC 바로가기 [Article Type] Communication
QT prolongation with hydroxychloroquine and azithromycin for the treatment of COVID-19: The need for pharmacogenetic insightsCOVID-19 치료를 위한 하이드록시클로로퀸 및 아지트로마이신을 사용한 QT 연장: 약리학적 통찰력의 필요성Comment Published on 2020-10-012022-09-11 Journal: Journal of cardiovascular electrophysiology [Category] SARS, 유전자 메커니즘, [키워드] Abstract arrhythmia Azithromycin COVID-19 Hydroxychloroquine ion channels pharmacogenetic pharmacogenetics polymorphism QT prolongation Treatment [DOI] 10.1111/jce.14722 PMC 바로가기 [Article Type] Comment